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Background: Raloxifene and alendronate are anti-resorptive therapies approved for the prevention and treatment
of postmenopausal osteoporosis. Raloxifene is also indicated to reduce the risk of invasive breast cancer in
postmenopausal women with osteoporosis and in postmenopausal women at high risk of invasive breast cancer. A
definitive study comparing the fracture effectiveness and rate of breast cancer for raloxifene and alendronate has
not been published. The purpose of this retrospective cohort study was to evaluate fracture and breast cancer rates
among patients treated with raloxifene or alendronate.
Methods: Females ≥45 years who initiated raloxifene or alendronate in 1998–2006 Truven Health Analytics
MarketScanW Databases, had continuous enrollment 12 months prior to and at least 12 months after the index
date, and had a treatment medication possession ratio ≥80% were included in this study. Rates of vertebral and
nonvertebral fractures and breast cancer during 1, 3, 5, 6, 7, and 8 years of treatment with raloxifene or alendronate
were evaluated. Fracture rates were adjusted for potential treatment bias using inverse probability of treatment
weights. Multivariate hazard ratios were estimated for vertebral and nonvertebral fractures.
Results: Raloxifene patients had statistically significantly lower rates of vertebral fractures in 1, 3, 5, and 7 years and
for nonvertebral fractures in 1 and 5 years. There were no statistically significant differences in the adjusted fracture
rates between raloxifene and alendronate cohorts, except in the 3-year nonvertebral fracture rates where raloxifene
was higher. Multivariate hazard ratios of raloxifene versus alendronate cohorts were not significantly different for
vertebral and nonvertebral fracture in 1, 3, 5, 6, 7, and 8 years. Unweighted and weighted breast cancer rates were
lower among raloxifene recipients.
Conclusions: Patients treated with alendronate and raloxifene had similar adjusted fracture rates in up to 8 years of
adherent treatment, and raloxifene patients had lower breast cancer rates.
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Osteoporosis is the most common bone disease in the
United States, affecting approximately 10 million
Americans with an additional 34 million people at risk
[1]. Osteoporosis contributes to more than 1.5 million
fractures each year and is the primary underlying cause
of fractures in the elderly [2]. Millions of individuals
are at risk for fracture due to risk factors such as low
bone mass and advanced age [1,3]. It is expected that in* Correspondence: fostersa@lilly.com
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reproduction in any medium, provided the or2025 there will be as many as 3 million osteoporotic-
related fractures in the United States [4].
Alendronate and raloxifene are anti-resorptive therapies
approved for the prevention and treatment of postmeno-
pausal osteoporosis. Alendronate is incorporated into the
bone matrix and acts to inhibit osteoclasts [5,6]. Raloxi-
fene binds to estrogen receptors and appears to act as an
estrogen agonist in bone [7]. Both drugs reduce bone
turnover and increase bone mineral density, though
alendronate has a stronger effect on these domains than
raloxifene [8]. Raloxifene is also indicated to reduce the
risk of invasive breast cancer in postmenopausal women
with osteoporosis and in postmenopausal women at hightd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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indicated for the treatment of invasive breast cancer,
reduction of the risk of recurrence of breast cancer, or
reduction of the risk of noninvasive breast cancer. Al-
though both therapies have established efficacy from
randomized clinical trials, comparative, real-world evi-
dence on these therapies for post-menopausal women
may provide important information for health care pro-
viders to supplement the clinical trial evidence.
A definitive study comparing the fracture effectiveness
of raloxifene and alendronate has not been published
[11]. The EVA trial (Evista Alendronate Comparison
trial) was designed to be the first double-blind, random-
ized comparison trial to compare osteoporosis therapies
head-to-head for fracture risk reduction among 3,000
postmenopausal women [11]. However, the study en-
rollment was stopped early due to difficulties with
timely recruitment of treatment naïve women. Only 122
patients reached the 2-year endpoint, and the statistical
power became too low for establishing non-inferiority
between drugs for fracture risk reduction.
We conducted a retrospective database study examining
patients who initiated raloxifene or alendronate and were
adherent to treatment during 6 time periods. Vertebral
and nonvertebral fracture rates were compared during
each respective treatment period. Due to the clinical im-
portance of breast cancer risk reduction in some postmen-
opausal women with osteoporosis, we also compared
breast cancer rates in the raloxifene and alendronate
cohorts. However, we did not specifically examine the
rates of invasive breast cancer versus the rates of recurrent
breast cancer or noninvasive breast cancer.
Methods
Data source
Study samples were drawn from 1998 to 2008 Truven
Health Analytics MarketScanW Commercial Claims and
Encounters (CCAE) and Medicare Supplemental and
Coordination of Benefits (COB) Databases (MDCR).
Both databases contain de-identified health insurance
enrollment information and claims data for inpatient
and outpatient medical services as well as outpatient pre-
scriptions. Enrollee demographic information is available
and medical claims include key data elements such as
service date, treatment setting, diagnosis, procedure, and
provider type. The CCAE database includes employees,
spouses, and dependents covered by employer-sponsored
private health insurance. The MDCR database profiles the
healthcare experience of retirees with Medicare supple-
mental insurance paid by employers. Together, both
databases consist of an average of 19 million lives an-
nually during the study period of 1998 to 2008. The pa-
tient data used in this analysis were de-identified in
compliance with the Health Insurance Portability andAccountability Act (HIPAA) regulations; thus, the study
did not require Institutional Review Board approval.
Patient selection
Female patients who initiated raloxifene or alendronate
between 1/1/1998 and 12/31/2006 were identified. The
index date was the first prescription date of raloxifene
or alendronate and patients were assigned to a treat-
ment cohort based on their initial prescription. Patients
were excluded if they were under age 45 at index or did
not have 12 months of continuous enrollment prior to
and minimum of 12 months of continuous enrollment
following the index date. Patients were required to have
days supply of 1–180 on their initial prescription, have
no osteoporosis medications in the pre-period, and no
osteoporosis medications other than the index medica-
tion during the post-period. Patients with Paget’s disease
during the pre- or post-periods were excluded. Patients
were followed from 12 months prior to treatment initi-
ation until the end of insurance eligibility or study end
(June 30, 2008), whichever came first. Medication
possession ratio (MPR) was evaluated for the follow-up
periods starting from treatment initiation. Since we
were interested in both early and later changes during
treatment with raloxifene and alendronate, we measured
MPR in 1-, 3-, 5-, 6-, 7-, and 8-year cohorts. Later
changes were measured more frequently due to the
anticipated smaller sample sizes as the follow-up period
lengthened. Patients who had MPR of 80% or higher on
their index medication during the follow-up period and
at least 90 days of continuous treatment from the index
date were considered adherent and included in the final
study samples (Figure 1).
Outcomes
The study’s primary endpoints were the comparative
vertebral and nonvertebral fracture rates (i.e. the per-
cent of patients having a fracture) among patients with
1, 3, 5, 6, 7, and 8 years of adherent treatment with
raloxifene versus alendronate. Fracture rates were com-
pared between treatment groups during 6 separate ob-
servation periods. Multivariate models were used to
estimate the hazard ratios of fractures in the 6 cohorts.
Additionally, a sensitivity analysis excluding patients
with any pre-index fracture diagnosis was performed in
the 3-year cohort.
The rate of breast cancer (i.e. the percent of patients
having breast cancer) during 1, 3, 5, 6, 7, and 8 years of
treatment with raloxifene versus alendronate was also
evaluated. A sensitivity analysis was conducted excluding
pre-index breast cancer.
Fracture was identified by primary or secondary diagno-
sis (International Classification of Disease, 9th Edition,
Clinical Modification [ICD-9-CM]) indicating a fracture
Figure 1 Patient sample selection. ALN=alendronate; MPR=medication possession ratio; RLX=raloxifene.
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room, or outpatient service. Diagnostic claims, such as
lab or radiology claims, were excluded since they do not
conclusively confirm the presence of a fracture. Frac-
tures due to trauma, identified either by an E code for
motor vehicle accident on the same claim, or by 3 or
more different fractures within 7 days before or after
the fracture of interest, were excluded. Additionally,
open fractures were excluded because they are more
likely to be related to trauma rather than osteoporosis
[12]. Pathological fractures were included if patients
were verified as not having cancer prior to and within
6 months after the pathological fracture diagnosis was
observed. This is consistent with the recommendation
by Curtis and colleagues to include pathological fracturesin epidemiologic studies of osteoporotic fractures [13]. In
addition, stress fractures were included. In order to appro-
priately identify treatment-emergent fractures, fractures
occurring during the first 90 days of follow-up were
excluded. This was similar to the method Meijer and col-
leagues used in assessing the impact of compliant osteo-
porosis treatment on fracture risk [14].
The occurrence of fracture during the post-period was
identified and fracture rates were calculated for clinical
vertebral fracture and nonvertebral fracture (hip, upper
leg, lower leg, pelvis, humerus, wrist/forearm, clavicle/rib,
and other). Fracture sites were determined by 3-digit ICD-
9-CM diagnosis codes. Due to the difficulty of using med-
ical claims to positively identify new fractures at the same
site or to distinguish fractures of the right arm/leg from
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was counted.
Breast cancer was identified by either ICD-9-CM diag-
nosis codes or ICD-9-CM and CPT procedure codes indi-
cating surgical procedure to treat breast cancer. Binary
variables were created to flag the presence of breast cancer
in the pre-period and in the 6 follow-up periods. A sensi-
tivity analysis was performed by evaluating breast cancer
rates in the post-period in patients without a code indica-
tive of breast cancer in the pre-period.
Statistical analysis
The results were adjusted for potential confounding
using inverse probability of treatment weights (IPTWs)
[15-17]. First, a binary logistic regression model was fit-
ted to calculate the propensity score, the probability of a
subject initiating raloxifene versus alendronate, condi-
tional on the observed baseline covariates. IPTWs were
created using the propensity score: for the raloxifene
cohort, the IPTW was [1/propensity score]; for the
alendronate cohort, the IPTW was [1/(1 – propensity
score)]. The outcomes were weighted by applying the
IPTWs to each observation. Covariates in the logistic
regression model included demographic characteristics
(age, Medicare eligibility, region, urban residence, insur-
ance capitation status, and provider type that was clos-
est to the fill date of index prescription), baseline Deyo
Charlson Comorbidity Index, pre-period bone mineral
density (BMD) screening or mammography, presence of
pre-index fracture, presence of baseline comorbid con-
ditions (HIV/AIDs, liver disease, cancer, osteoporosis,
renal disease, rheumatoid arthritis, heart disease, hyper-
tension, gastric disease, vasomotor symptoms, osteo-
necrosis of the jaw, diabetes, alcoholism, deep venous
thrombosis/pulmonary embolism, osteodystrophy, thyroid
disease, metabolic disorders, dysphagia, and dyslipidemia),
and pre-period use of other medications (glucocorticoids,
immunosuppressants, anticonvulsants, estrogen/hormone
therapy, hormone deprivation therapy, prescription aspirin/
acetaminophen, NSAIDS, opioids, benzodiazepines, and
skeletal muscle relaxants).
Statistical tests of significance for differences between
raloxifene and alendronate were conducted. Chi-square
tests were used to evaluate the statistical significance of
differences for categorical variables; independent t tests
were used for evaluating significance of continuous
variables. To assess the validity of propensity score
weighting, standardized differences were calculated to
assess group balances before and after the weights were
applied to the variables entered as covariates in the
propensity model [18].
To further adjust for the remaining imbalances between
the raloxifene and alendronate cohort, we obtained the
hazard ratios for vertebral and nonvertebral fractures in 6separate observation periods. In the nonvertebral fracture
model, patients could potentially have multiple fractures
of different sites during the observation period. For
example, a patient could have a fracture of the lower leg
and then later a hip fracture. Under this circumstance, the
marginal proportional hazards model is considered as an
appropriate specification [19] and was used to obtain an
overall hazard ratio for the hazard of multiple fractures.
For the vertebral fracture model, the hazard ratio was
obtained using the standard Cox model since we only cap-
tured a patient’s first vertebral fracture event due to the
challenge of identifying subsequent fracture at the same
fracture site using administrative claims. Alendronate
served as the reference group in all models. The models
were weighted using the IPTWs and the same list of co-
variates was included in all models: age, pre-index BMD
screening or mammography, pre-index use of glucocor-
ticoids, immunosuppressants, anticonvulsants, aspirin/
acetaminophen, NSAIDS, opioids, benzodiazepines, skel-
etal muscle relaxants, pre-index dyslipidemia, rheumatoid
arthritis, heart disease, vasomotor symptoms, gastric
disease, osteoporosis, and fracture. A sensitivity analysis
was conducted which excluded patients with a pre-index
fracture diagnosis for the 3-year cohort.
Results
Patient characteristics
Six cohorts were identified based on the length of
adherent therapy: 1 year (raloxifene [n = 23,243],
alendronate [n = 72,055]); 3 years (raloxifene [n = 9,758],
alendronate [n = 24,221]); 5 years (raloxifene [n =
3,141], alendronate [n = 6,652]); 6 years (raloxifene [n =
1,246], alendronate [n = 2,465]); 7 years (raloxifene
[n = 650], alendronate [n = 1,053]); and 8 years (raloxifene
[n = 217], alendronate [n = 331]). Pre-period demographic
and clinical characteristics are presented in Table 1. The
mean age ranged between 60.7 and 65.3 years. Patients
in the raloxifene cohorts were approximately 2 years
younger than those in the alendronate cohorts (p < 0.001).
The most common pre-period conditions were hyperten-
sion, “other cardiovascular disease” (ICD-9-CM diagnosis
codes 390.xx - 459.xx, excluding ischemic heart disease
and hypertension), metabolic disorders, osteoporosis, and
diabetes. The raloxifene cohorts had more patients
with hypertension, diabetes, and dyslipidemia than the
alendronate cohorts and differences were statistically sig-
nificant in the 1-, 3-, and 5-year cohorts. Significantly
higher pre-period prevalence of other cardiovascular dis-
ease, osteoporosis, rheumatoid arthritis and breast cancer
was found among patients treated with alendronate. The
number of patients having BMD screening was consist-
ently lower in the raloxifene cohorts by a margin of 27.0
to 40.7 percentage points (p < 0.001). After applying the
IPTWs, the differences in the majority of demographic
Table 1 Unweighted patient demographic and baseline clinical characteristicsa
1-Year 3-Year 5-Year 6-Year 7-Year 8-Year
RLX ALN RLX ALN RLX ALN RLX ALN RLX ALN RLX ALN
Number of Patients 23,243 72,055 9,758 24,221 3,141 6,652 1,246 2,465 650 1,053 217 331
63.0 64.9 63.3 65.2 63.0 65.3 62.9 64.7 62.3 64.3 60.7 63.2
Age (Mean, SD) (9.5) (10.7)* (9.1) (10.3)* (8.8) (10.0)* (9.0) (9.8)* (8.8) (9.6)* (7.6) (9.0)*
Insurance Plan Typesb * * * *
Comprehensive 43.0% 41.6% 50.0% 49.8% 55.8% 54.3% 55.9% 50.6% 60.9% 65.9% 54.4% 61.9%
Preferred provider
organization
35.4% 33.9% 31.7% 29.6% 25.9% 23.8% 21.7% 19.1% 19.2% 14.5% 20.3% 11.8%
Point-of-service plan with
capitation
6.1% 4.9% 7.4% 7.5% 11.3% 14.5% 17.9% 26.3% 16.3% 17.0% 23.5% 24.2%
Point-of-service plan 8.7% 6.9% 7.7% 5.7% 5.7% 4.3% 4.2% 3.8% 3.2% 2.5% 1.4% 1.8%
Health maintenance
organization
6.1% 11.7% 3.0% 7.0% 1.1% 2.9% 0.3% 0.2% 0.3% 0.1% 0.5% 0.3%
Other/Unknown 0.6% 0.9% 0.2% 0.3% 0.1% 0.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Medicare Eligibility 38.1% 46.0%* 41.4% 49.3%* 41.8% 52.1%* 42.1% 50.8%* 39.4% 49.0%* 28.1% 40.8%†



























BMD Screening 44.4% 71.4%* 40.0% 69.9%* 33.4% 68.5%* 34.0% 70.3%* 31.1% 70.2%* 24.9% 65.0%*
Pre-period Fracture 3.9% 7.7%* 3.5% 6.8%* 2.8% 5.8%* 3.4% 6.2%* 2.9% 6.3%† 3.2% 5.7%
Confounding Conditions
Hypertension 26.6% 25.2%* 27.4% 24.9%* 27.9% 24.6%* 28.4% 25.7% 28.0% 24.6% 29.0% 21.8%
Other Cardiovascular
Disease
17.6% 20.0%* 17.3% 19.8%* 16.5% 19.6%* 15.5% 19.1%† 14.6% 19.6%† 13.4% 20.2%†
Metabolic Disorders 15.6% 14.9%† 15.1% 14.3% 15.0% 13.8% 13.6% 13.4% 14.2% 13.7% 17.1% 14.8%
Diabetes 9.2% 7.8%* 9.8% 7.0%* 8.9% 6.4%* 8.0% 6.1%† 8.3% 5.9% 8.8% 7.3%
Osteoporosis 9.4% 12.9%* 8.4% 13.2%* 7.6% 13.2%* 7.2% 13.8%* 7.8% 14.7%* 9.7% 16.3%†
Dyslipidemia 7.0% 6.2%* 6.9% 6.1%† 6.8% 5.7%† 6.4% 5.4% 7.1% 5.2% 8.3% 4.5%
Rheumatoid arthritis 1.7% 2.2%* 1.5% 2.2%* 1.1% 2.1%* 1.1% 2.4%† 1.2% 2.4% 1.4% 1.8%
Vasomotor symptoms 4.1% 3.5%* 4.3% 4.1% 4.1% 4.9% 3.8% 6.0%† 3.2% 7.3%* 1.4% 7.9%*
Ischemic heart disease 7.5% 7.5% 7.4% 7.6% 7.3% 7.6% 6.7% 7.2% 5.4% 6.6% 4.1% 6.9%
Breast cancer 4.8% 6.2%* 4.5% 5.8%* 5.0% 5.3% 5.9% 5.8% 5.4% 6.4% 5.5% 6.6%
Reflux 3.8% 2.7%* 3.7% 2.3%* 3.6% 2.5%† 3.6% 2.4%† 3.5% 2.1% 2.8% 2.1%
Gastritis 1.8% 1.4%* 1.5% 1.3% 1.4% 1.4% 0.9% 1.5% 1.1% 1.9% 0.5% 3.0%†
Gastric ulcer 0.4% 0.2%* 0.3% 0.2% 0.2% 0.2% 0.1% 0.1% 0.0% 0.2% 0.0% 0.3%
Peptic ulcer 0.1% 0.1%† 0.1% 0.1% 0.1% 0.1% 0.2% 0.1% 0.3% 0.2% 0.5% 0.0%
Confounding Medications
Glucocorticoids 17.6% 19.1%* 16.4% 16.7% 16.0% 15.2% 15.0% 15.8% 13.1% 15.6% 12.0% 14.8%
Anticonvulsants 6.1% 6.6%† 5.3% 5.2% 4.4% 4.5% 4.1% 3.8% 4.0% 2.9% 3.2% 2.7%
Immunosuppressants 1.7% 3.1%* 1.4% 2.5%* 1.1% 2.3%* 0.7% 2.2%† 0.9% 2.7%† 0.9% 3.3%
Hormone Deprivation
Therapy
2.2% 3.8%* 2.0% 3.5%* 2.4% 2.9% 2.8% 2.8% 2.5% 2.5% 2.8% 3.3%
Estrogen/Hormone Therapy 43.3% 29.7%* 50.3% 38.2%* 52.6% 45.5%* 38.0% 43.3%† 36.5% 42.4%† 36.4% 41.1%
Pre-period All-cause
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Table 1 Unweighted patient demographic and baseline clinical characteristicsa (Continued)
Provider closest to Index
Prescription
Specialist 38.6% 37.5%† 38.9% 38.8% 39.4% 40.5% 43.1% 43.0% 39.8% 41.2% 38.7% 40.5%
Primary Care 17.0% 17.1% 15.9% 16.4% 15.7% 14.8% 14.2% 15.1% 14.2% 16.6% 13.4% 16.6%
Other/Unknown 44.4% 45.4%† 45.3% 44.8% 44.9% 44.8% 42.7% 42.0% 46.0% 42.2% 47.9% 42.9%
*P<0.001; †P<0.05.
aDue to limited space, not all covariates included in the IPTW and Multivariate models are presented in Table 1. Data can be provided upon request.
bChi-Square test is used to test differences in insurance plan type between RLX and ALN cohort.
ALN=alendronate; BMD=bone mineral density; RLX=raloxifene; SD=standard deviation.
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between the raloxifene and alendronate cohorts. Most
variables reached a desirable balance between cohorts
as the standardized differences were below 10 [20]. A
few exceptions included rural residence in the 7-year
follow-up period and gastritis in the 8-year cohorts.
Pre-period fractures
Prior to beginning treatment, a lower proportion of pa-
tients treated with raloxifene had a fracture compared
to patients treated with alendronate. Differences in pre-
period fracture rates ranged from 2.5 to 3.8 percentage
points and these differences were significant with the
exception of the 8-year cohorts (Table 1). After applying
the IPTWs, the pre-period fracture rates for the raloxi-
fene cohorts became higher than the alendronate co-
horts in the 1-year (7.9%/raloxifene versus 6.8%/
alendronate, p < 0.001), 3-year (7.5% versus 5.9%, p < 0.001),
and 5-year (7.2% versus 5.0%, p < 0.001) follow-up
period. The weighted pre-period fracture rates were not
significantly different between patients treated with
raloxifene and alendronate in the 6-year (6.3% versus
5.5%, p = 0.305), 7-year (4.5% and 5.1%, p = 0.563), and
8-year cohort (3.7% versus 5.0%, p = 0.455).
Rate of vertebral and nonvertebral fracture
Before applying the IPTWs, patients treated with raloxi-
fene appeared to have lower fracture rates during the
treatment period than patients treated with alendronate.
Patients with 1, 3, 5, and 7 years of adherent treatment
with raloxifene had significantly lower rates of vertebral
fracture than patients treated with alendronate. The pa-
tients treated with raloxifene had statistically significantly
lower nonvertebral fracture rates in the 1- and 5-year
follow-up periods (Table 2).
After applying the IPTWs, no statistically significant
differences were found in the rates of vertebral fractures
between the raloxifene and alendronate cohorts in all 6
time periods. There were also no statistically significant
differences in the rates of nonvertebral fractures between
the raloxifene and alendronate cohorts in each of the time
periods, with the exception of the 3-year cohort (7.3%/
raloxifene versus 6.7%/alendronate, p = 0.034).Risk of fracture
We examined the risk of fracture in the 6 observation
periods by evaluating time to fracture as shown in Figure 2.
The hazard ratios were not significantly different from 1
for vertebral fracture or for nonvertebral fracture in all six
observation periods, indicating no significant difference in
the risk of vertebral and nonvertebral fracture during 1, 3,
5, 6, 7,and 8 years of adherent treatment with raloxifene
and alendronate.
The sensitivity analysis including only patients without
pre-index fracture and examining the risk of vertebral
and nonvertebral fracture in the 3-year cohort showed
similar findings. There were no statistically significant
differences in the risk of vertebral fracture (HR = 0.78,
95% CI: 0.56 – 1.09, p = 0.149) or nonvertebral fracture
(HR = 1.06, 95% CI: 0.95 – 1.19, p = 0.287) during 3 years
of adherent treatment with raloxifene or alendronate.Rate of breast cancer
Rates of breast cancer in the raloxifene cohorts were
significantly lower than in the alendronate cohorts. The
absolute difference in rates increased with increasing
duration of follow-up. In 1, 3, 5, 6, 7, and 8 years of
treatment, the unweighted breast cancer rates were 1.6
(p < 0.001), 1.8 (p < 0.001), 2.3 (p < 0.001), 2.1 (p = 0.051),
3.9 (p = 0.015), and 6.5 (p = 0.018) percentage points lower
for the raloxifene cohorts than the alendronate cohorts,
respectively. Figure 3 displays the breast cancer rates
weighted by applying IPTWs. The weighted rates were sig-
nificantly lower in raloxifene cohorts by 1.0-7.6 percentage
points. In the sensitivity analyses, which excluded pre-
existing breast cancer cases, differences in the 1- and
3-year cohorts in rate of breast cancer were not
observed. However, significantly lower breast cancer
rates were found in the raloxifene cohorts compared to
the alendronate cohorts in the longer follow-up periods.
The risk of newly diagnosed breast cancer, weighted
using the IPTWs, was 1.6 (p < 0.001), 3.0 (p < 0.001), 3.7
(p = 0.002), and 5.6 (p = 0.004) percentage points lower
among the raloxifene recipients than their alendronate
counterparts in the 5-, 6-, 7-, and 8-year follow-up cohorts,
respectively.
Table 2 Unweighted and weighted fracture rates in 1, 3, 5, 6, 7, 8 years of adherent treatment with RLX and ALN
Length of
followup























1-year 0.19% 0.13% 0.25% 0.30% 0.27% 0.35% 0.002 0.34% 0.31% 0.38% 0.30% 0.27% 0.34% 0.334
3-years 0.67% 0.50% 0.83% 1.00% 0.89% 1.14% 0.002 0.93% 0.83% 1.03% 0.97% 0.87% 1.08% 0.720
5-years 0.92% 0.59% 1.26% 1.70% 1.40% 2.03% 0.002 1.48% 1.25% 1.71% 1.69% 1.43% 1.94% 0.451
6-years 1.20% 0.60% 1.81% 1.99% 1.44% 2.54% 0.083 1.28% 0.93% 1.64% 1.90% 1.46% 2.34% 0.169
7-years 1.38% 0.49% 2.28% 3.10% 2.08% 4.19% 0.024 2.14% 1.46% 2.82% 3.11% 2.29% 3.94% 0.231
8-years 0.92% 0.00% 2.19% 3.32% 1.39% 5.25% 0.071 3.70% 2.12% 5.27% 3.80% 2.19% 5.41% 0.952
Nonvertebral
Fracture
1-year 1.96% 1.78% 2.14% 2.20% 2.10% 2.31% 0.023 2.36% 2.27% 2.45% 2.15% 2.06% 2.24% 0.056
3-years 6.48% 5.99% 6.97% 6.80% 6.48% 7.12% 0.281 7.31% 7.04% 7.58% 6.70% 6.40% 6.93% 0.034
5-years 9.71% 8.67% 10.75% 11.80% 11.05% 12.61% 0.002 10.73% 10.14% 11.33% 11.48% 10.85% 12.12% 0.271
6-years 12.36% 10.53% 14.19% 13.18% 11.85% 14.52% 0.479 13.99% 12.89% 15.10% 12.99% 11.90% 14.07% 0.395
7-years 13.85% 11.19% 16.50% 15.29% 13.12% 17.46% 0.414 17.53% 15.74% 19.32% 15.29% 13.58% 17.01% 0.222
8-years 15.67% 10.83% 20.50% 18.73% 14.53% 22.93% 0.356 12.97% 10.16% 15.78% 18.82% 15.53% 22.12% 0.071
ALN=alendronate; RLX=raloxifene.
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This study examined fracture risk reduction during adher-
ent use of raloxifene and alendronate in claims data.
Patients treated with raloxifene were younger, had a lower
pre-period incidence of fracture, and had a lower inci-
dence of osteoporosis diagnosis than patients treated with
alendronate. After adjusting for baseline demographic and
clinical characteristics by applying the IPTWs, the rates of
vertebral and nonvertebral fracture were not significantly
different between the patients treated with alendronate
and raloxifene in most of the follow-up periods examined.
In the 3-year cohort, there was no significant difference
in vertebral fracture but a significant difference in
nonvertebral fracture (7.3%/raloxifene versus 6.7%/
alendronate, p = 0.034) was observed. Once time-to-frac-
ture was taken into consideration, no significant difference
in the risk of vertebral or nonvertebral fracture was found
in all 6 observation periods. In addition, a similar result
was observed when restricting to patients without pre-
index fracture in the 3-year cohort. These results suggest
that patients experienced a similar reduction in fracture
risk during treatment with raloxifene and alendronate.
Randomized clinical trials (RCTs) and claims based
retrospective studies examining the effectiveness of
bisphosphonates and raloxifene have been published
[5-7,9,21-23]. The Multiple Outcomes of Raloxifene
Evaluation (MORE) trial found the relative risk of
nonvertebral fracture (excluding traumatic fractures) forpatients treated with raloxifene was not significantly differ-
ent from patients receiving placebo after 3 years (RR = 0.9,
95% CI: 0.8 - 1.1) [7] and 4 years of observation (RR = 0.93,
95% CI: 0.81 - 1.06) [23]. In the Fracture Intervention Trial
(FIT) of the effect of alendronate, the relative risk of
nonvertebral fracture (excluding traumatic fractures)
was 0.88 (95% CI: 0.74 - 1.04) among patients without
a baseline vertebral fracture at 4 years [6] and 0.80
(95% CI: 0.63 - 1.01) among patients with a baseline
vertebral fracture at 3 years [5]. In a double-blind, random-
ized comparison of patients treated with alendronate or ral-
oxifene, Recker and colleagues examined postmenopausal
women with a femoral neck BMD T-score between −2.5
and −4.0, inclusive, no prevalent vertebral fractures, and
no prior bone-active agent use [11]. Although the trial was
stopped early, resulting in insufficient power to show non-
inferiority between therapies, the primary endpoint of ≥1
new osteoporotic vertebral or nonvertebral fracture
occurred in 22/713 alendronate (3.1%) patients and 20/
699 raloxifene (2.9%) patients.
Cadarette and colleagues published an insurance
claims-based cohort study of 43,135 patients aged at
least 65 years who initiated oral bisphosphonates, nasal
calcitonin, or raloxifene while enrolled in 2 statewide
pharmaceutical benefit programs [21]. The mean age
was 79 years and 96% were women. The primary out-
come was nonvertebral fracture (hip, humerus, or radius
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RLX ALN
Figure 3 Weighted breast cancer rates in 1, 3, 5, 6, 7, and 8
years of adherent treatment with RLX and ALN, all patients.
*P-value<0.001; †P-value<0.01. 95% confidence intervals: RLX: 1 year
(4.75%-5.02%), 3 year (6.87%-7.41%), 5 year (7.31%-8.34%), 6 year
(8.13%-9.95%), 7 year (7.34%-9.99%), 8 year (3.58%-7.38%); ALN: 1 year
(5.73%-6.03%), 3 year (7.88%-8.47%), 5 year (9.46%-10.65%), 6 year
(11.01%-13.11%), 7 year (11.98%-15.25%), 8 year (10.29%-15.99%).
ALN=alendronate; RLX=raloxifene.
Figure 2 Hazard ratios of RLX versus ALN for vertebral fracture and nonvertebral fracture in 1, 3, 5, 6 , 7 and 8-year cohorts, all
patients (ALN served as the reference group). For nonvertebral fracture, hazard ratios were fitted based on marginal models which adjusted
for the clustering of multiple events. For vertebral fracture, hazard ratios were fitted based on standard Cox models. P>0.05 in all models.
ALN=alendronate; HR=hazard ratio; RLX=raloxifene.
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ture risk were not found between alendronate,
risedronate, and raloxifene. However, among those with
a fracture history, patients treated with raloxifene expe-
rienced more nonvertebral fractures within 12 months
(HR = 1.78, 95% CI: 1.20 to 2.63) compared with those
treated with alendronate.
The Cadarette et al. study included Medicare enrollees
from 2 states with an average age of 79 years, whereas our
study included patients with both commercial and Medi-
care supplemental insurance, with an average age of 61 to
65 years old. In the Cadarette et al. study, an intent-to-
treat approach was used and patients were only required
to receive treatment with raloxifene or bisphosphonate at
index. Our study took an on-treatment approach and
required a minimum MPR of 80% of index medication in
each of the follow-up periods. Additionally, patients were
required not to switch to another osteoporosis medication
during the follow-up period. Our study examined fracture
rates during longer treatment periods including 3-, 5-,
6-, 7-, and 8-year cohorts. In addition to nonvertebral
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and found no significant differences between adherent
treatment of raloxifene and alendronate. Our sensitivity
analysis based on only patients without pre-index fracture
confirmed that there was no significant difference in the
risk of vertebral or nonvertebral fracture after 3 years of
adherent treatment with raloxifene or alendronate.
Raloxifene has been shown to reduce the risk of inva-
sive breast cancer in postmenopausal women with
osteoporosis and in postmenopausal women at high risk
for invasive breast cancer [9,10]. Recent analysis has
suggested that bisphosphonates might also reduce the
risk of breast cancer [24]. In this study, the rate of
breast cancer was lower in the raloxifene group com-
pared with the alendronate group and the gap between
the groups increased in the cohorts with longer dur-
ation of follow-up.
Consistent with previous studies, [21,25] we found that
patients treated with raloxifene were younger, less likely
to be diagnosed with osteoporosis and have BMD
screening, and had lower rates of pre-period fracture
than those treated with alendronate. We used IPTW
methodology to adjust for these and other confounders
and achieved cohort balance after weighting. Due to the
limitations of administrative claims data, we were unable
to adjust for clinical risk factors such as BMD score.
Only clinically-diagnosed fractures recorded in medical
claims were analyzed. We included closed fracture,
pathological, and stress fracture as a proxy of
osteoporosis-related fracture but we were unable to re-
view patients’ medical records to validate this assump-
tion. Due to the difficulty of identifying re-fracture of
the same fracture site using medical claims, we only
reported the first fracture at a given fracture site. This is
a conservative approach with inherent underestimation
of the fracture rate. Patients were required to be eligible
for insurance and adherent with their medication during
the fixed-length period and could not switch to another
study medication. This could potentially underestimate
the fracture rate, but the same criteria were applied to
both treatment groups. This study was not designed to
specifically evaluate reduction of breast cancer risk thus
we did not specifically control for risk factors such as
family history of breast cancer. Additionally, the sample
sizes of longer follow-up length cohorts were small
which should be taken into consideration when evaluat-
ing these findings. Finally, these findings may not be
generalizable to populations outside of those evaluated
in this study.
Conclusions
Fracture is the major consequence of osteoporosis and
prevention of fracture is central to cost containment in
the management of osteoporosis. In this study, raloxifene-and alendronate-treated patients had similar weighted
fracture rates, and raloxifene-treated recipients had lower
rates of breast cancer.
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